NEP INTERLONG (08329) subsidiary Haiwang Changjian and Huikang Biotech entered into a Joint Venture Agreement for the establishment of a joint venture company.

NEP INTERLONG (08329) announced that on September 14, 2026 (after trading hours), Haiwang Changjian, a wholly-owned subsidiary of the Company, and Huikang Biotech (a non-wholly-owned subsidiary of Jinbaihui) entered into a Joint Venture Agreement for the establishment of a joint venture company. Pursuant to the Joint Venture Agreement, the proposed registered capital of the joint venture company is RMB 5 million, of which Haiwang Changjian shall subscribe for capital contribution of RMB 3.5 million (accounting for 70% equity interest in the joint venture company), and Huikang Biotech shall subscribe for capital contribution of RMB 1.5 million (accounting for 30% equity interest in the joint venture company). Each party shall pay its capital contribution as agreed within one year from the date of completion of the industrial and commercial registration of the joint venture company. The parties agreed to jointly contribute capital to establish the joint venture company, which is positioned as a company focusing on the field of early tumor screening and in vitro diagnostics (IVD), providing products, sales and overall solutions. The joint venture company shall be organized as a limited liability company, with shareholders bearing liability to the company to the extent of their respective subscribed capital contributions, and the joint venture company bearing liability for its debts with all of its assets. The operating term is tentatively set at 10 years, commencing from the date of issuance of the business license. The business scope of the joint venture company is tentatively set as: technical services, technical development, technical consulting, technical exchange, technical transfer, technical promotion; health consulting services (excluding diagnostic and therapeutic services); data processing services; sales of Class I and Class II medical devices; sales of medical consumables; import and export of goods and import and export of technology, etc., subject to the approval and registration by the industrial and commercial authorities. The Group continues to advance its strategic layout in the healthcare and in vitro diagnostics-related fields. Through the establishment of the joint venture company with Huikang Biotech, the parties will integrate resources in research and development, products, channels and markets, achieve technology transformation and commercialization in the early tumor screening and IVD tracks, optimize product structure, enhance operational efficiency and market coverage, and help the Group enrich its product lines, expand market share, strengthen core competitiveness and enhance shareholder returns. The Board considers that the Joint Venture Agreement was entered into on normal commercial terms, and its terms are fair and reasonable and in the overall interests of the Company and its shareholders.